@probstMD @ManiniAlex @painfreeED I'm pretty skeptical. Nav.8 is not as relevant for pain as Nav.7, which has not led to the holy grail of pain control despite significant research in the last 10ish years.
Buprenorphine is a hot topic at the ASPMN 33rd National Conference. Excellent to see this dedicated group of Nurses keeping on top of factors impacting and influencing pain management. I am honored to have been selected to contribute
@MarcRubyDPT@DrZoffness The pain neuroscience education field is a good place to find information on having these conversations. Explain Pain lexicon by Lorimar Moseley is my preference, but there are many others. Jo Nijs is another favorite.
@painfreeED@NarouzeMD@garyschwartzmd Neither neither used enough opioid to spare. If they used tylenol as the prn they could have been truly opioid free. In both groups.
Will recommendations for opioid discharge scripts impact diversion? Hopefully the audience will find out during my session at the ASPMN® 32nd National Conference. #ASPMNLEARNS - via #Whova event app
Daughter and son, nurse practitioner and physician reflect on a person’s request for medical assistance in dying under unusual circumstances: https://t.co/MobrorEJKG
@painfreeED My thoughts and understanding are the endocanabinoid system is too small a factor in the complexity of pain experiences to make a difference in large populations. But many people really enjoy cannabinoids. And there is lots of money to be made.
#AusPainSoc debate:
- evidence poor for most medications used for pain, not just cannabinoids, but harms overall lower
- prescribing of anything out of misguided compassion can lead to trouble (opioid lesson)
- shouldn’t prescribe something with no evidence of efficacy…